Business
Posting of 2023 Annual Report & Notice of the AGM
Posting of 2023 Annual Report & Notice of the AGM.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\n\n\n\n\nFor immediate release\n\n\n18 June 2024\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nPosting of the 2023 Annual Report and Notice of the Annual General Meeting\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report and Financial Statements for the year ended 31 December 2023, and the Notice of Annual General Meeting within it, have been posted to shareholders, and are available on the Company's website.\n \nThe Annual General Meeting will now be held at 12:00 pm on Thursday 11 July 2024 at the Surrey Technology Centre, Surrey Research Park, Guildford, Surrey GU2 7YG. The Board is looking forward to welcoming shareholders in person and will provide a business update after the formalities of the meeting are concluded.\n \n \n \nFor further information:\n \n\n\n\n\nANGLE plc\n\n\n+44 (0) 1483 343434\n\n\n\n\nAndrew Newland, Chief Executive\nIan Griffiths, Finance Director\n\n\n \n \n\n\n\n\n \nBerenberg (NOMAD and Broker)\nToby Flaux, Ciaran Walsh, Milo Bonser\n\n\n \n+44 (0) 20 3207 7800\n\n\n\n\n \nFTI Consulting\nSimon Conway, Ciara Martin\nMatthew Ventimiglia (US)\n\n\n \n \n+44 (0) 203 727 1000\n+1 (212) 850 5624\n\n\n\n\n \n \nNotes for editors\n \nAbout ANGLE plc\n \nANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 system enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.\n \nANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratories in the UK. Services include custom made assay development and clinical trial testing for pharma.\n \nOver 90 peer-reviewed publications have de...